Astria Therapeutics Inc expected to post a loss of 48 cents a share - Earnings Preview

Astria Therapeutics

05/05/2025 12:08

Astria Therapeutics Inc ATXS.OQ ATXS.O is expected to show no change in quarterly revenue when it reports  results on May 7 (estimated) for the period ending March 31 2025

​LSEG's mean analyst estimate for Astria Therapeutics Inc is for a loss of 48 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Astria Therapeutics Inc is $28.00​, above​ its last closing price of $5.36. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Dec. 31 2024
-0.45
-0.45
-0.20
Beat
55.7
Sep. 30 2024
-0.44
-0.42
-0.42
Met
0.4
Jun. 30 2024
-0.39
-0.38
-0.43
Missed
-11.7​
Mar. 31 2024
-0.37
-0.36
-0.38
Missed
-4.4
​​Dec. 31 2023
-0.78
-0.78
-0.94
Missed
-20.5
Sep. 30 2023
-0.46
-0.49
-0.63
Missed
-29.6​
Jun. 30 2023
-0.49
-0.49
-0.45
Beat
7.6
Mar. 31 2023
-0.57
-0.55
-0.40
Beat
27.5

This summary was machine generated May 5 at 11:08 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)